Share on Google Plus 1 Share on Twitter 2 Share on Facebook 5 Share on LinkedIn Share on PInterest Share on Fark! Share on Reddit Share on StumbleUpon Tell A Friend 8 (16 Shares)  
Printer Friendly Page Save As Favorite View Favorites (# of views)   7 comments

General News

They've nominated WHO to head the FDA?

By       Message Martha Rosenberg     Permalink
      (Page 1 of 1 pages)
Related Topic(s): ; ; ; ; ; ; , Add Tags Add to My Group(s)

Must Read 4   News 2   Supported 2  
View Ratings | Rate It Headlined to H3 9/17/15

Author 1353
Become a Fan
  (79 fans)
- Advertisement -

FDA nominee thinks being a Pharma consultant is a "very good thing"

Imagine a doctor who "served as a director, officer, partner, employee, advisor, consultant or trustee for Genentech" and reports 23 financial links to drug companies including stock ownership being FDA commissioner? A doctor who defends Merck's Vioxx behavior which cost thousands of lives and said "many of us consult with the pharmaceutical industry, which I think is a very good thing. They need ideas and then the decision about what they do is really up to the person who is funding the study," on PBS.

Big Pharma has friends in high places by Martha Rosenberg

The Obama administration has nominated Duke University researcher Robert Califf to be FDA commissioner ending all pretenses of a firewall between the drug industry and the government agency that is supposed to regulate it. In 2009 when Califf's name was floated for FDA commissioner along with three others, Reuters reported that medical experts asked how someone who helps drug companies market their products could possibly be considered as the nation's chief watchdog over unsafe medications. We now have our answer.

When Margaret Hamburg was named FDA commissioner in 2009, instead of Califf, many hoped her background as deputy health commissioner for New York City could purge industry influences, especially when she appointed Joshua Sharfstein deputy commissioner who also had a public health background. But hopes were dashed when Sharfstein left within two years and Hamburg soon moved to loosen conflict of interest rules governing who can sit on advisory committees that recommend drug approvals. In fact, Hamburg appointed Califf FDA Deputy Commissioner earlier this year, before stepping down

And there's more

- Advertisement -

Califf is not the only government official with blatant industry ties. Four years ago, the Chronicle of Higher Education reported that longtime director of the National Institute of Mental Health (NIMH) Thomas Insel assured the University of Miami medical school dean if they hired his friend, government money--our money--would not be denied to his school. Why would it be denied? The friend, Charles Nemerof, was found to have so much unreported Pharma income after a congressional investigation, a $9.3 million National Institutes of Health (NIH) grant he managed was suspended. At the time of the cronyism and promise of flowing government funds, Insel was leading NIH efforts to stamp out conflicts of interest reported the Chronicle.

Animal lovers know Insel as the former director of the Yerkes Regional Primate Research Center whose experiments recall those of Henry Harlow who created "Iron Maiden" mothers and "pit of despairs" for baby primates. In one Insel experiment, newborn monkeys were "removed from their mothers within 48 h of birth," and subjected to "stressors" without being "able to use a social companion to buffer their response to a stressor." What did researchers learn? "As expected from previous studies, monkeys removed from their mother shortly after birth and raised in standard nursery conditions develop a syndrome characterized by decreased affiliation, increased aggression, and increased self-directed, repetitive behavior," they write. Thanks for that.

At first, the news this week that Insel is leaving NIMH for Google looks innocuous. But Insel won't be enhancing mobile aps or tracking Google ads. Google is rapidly becoming part of Big Pharma and Insel is joining Google Life Sciences, a semi-secret research organization studying "brain diseases" which last year launched a potential $1.5 billion research partnership with drug maker AbbVie.

With the likely new head of the FDA an unapologetic Pharma consultant maybe the government has solved the problem of hidden and undisclosed conflicts of interest. They are not hidden and they are not undisclosed.

- Advertisement -


- Advertisement -

Must Read 4   News 2   Supported 2  
View Ratings | Rate It

Martha Rosenberg is an award-winning investigative public health reporter who covers the food, drug and gun industries. Her first book, Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health, is distributed by Random (more...)

Share on Google Plus Submit to Twitter Add this Page to Facebook! Share on LinkedIn Pin It! Add this Page to Fark! Submit to Reddit Submit to Stumble Upon

Go To Commenting

The views expressed in this article are the sole responsibility of the author and do not necessarily reflect those of this website or its editors.

Writers Guidelines

Contact AuthorContact Author Contact EditorContact Editor Author PageView Authors' Articles
- Advertisement -

Most Popular Articles by this Author:     (View All Most Popular Articles by this Author)

Grassley Investigates Lilly/WebMD link Reported by Washington Post

The Drug Store in Your Tap Water

It's the Cymbalta Stupid

Are You Sure You're Not Psychotic Asks Shameless Drug Company?

Another Poorly Regulated "Derivative"--the Antidepressant Pristiq

MRSA and More. Antibiotics Linked to Obesity and Allergies, Too